Clinical Trials on Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Total 1928 results

Mahidol University
Bayer

Completed

The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP

Diffuse Large B-cell Lymphoma

Thailand
Odense University Hospital
University of Southern Denmark

Unknown

The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.

Diffuse Large B-cell Lymphoma

Denmark
Fudan University

Unknown

R-ESHAP Followed by Autologous Transplantation for Refractory or Relapsed Diffused Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Shanghai CP Guojian Pharmaceutical Co., Ltd.

Completed

Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma

Diffuse Large B Cell Lymphoma

China
NKBio Co.Ltd.

Unknown

Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients (NKCell)

Diffuse Large B-cell Lymphoma

Korea, Republic of
Probiomed S.A. de C.V.

Unknown

TREatment of degeNerative and Neoplastic Diseases With Rituximab (TREND)

Diffuse Large B Cell Lymphoma

Mexico
International Extranodal Lymphoma Study Group (IELSG)

Active, not recruiting

Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (IELSG30)

Large B-cell Diffuse Lymphoma of Testis

Italy, Switzerland
Catherine Bollard

Active, not recruiting

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Hoffmann-La Roche

Completed

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Diffuse Large B-Cell Lymphoma (DLBCL) | Follicular NHL Grade 3b

Hong Kong, Thailand, Sweden, Taiwan, Mexico, Austria, Serbia, China, Czech Republic, Australia, Malaysia, Croatia, Israel, South Africa, Bosnia and Herzegovina, Brazil, Bulgaria, Estonia, Latvia, Macedonia, The Former Yugoslav... and more
Case Comprehensive Cancer Center

Completed

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Grade 3b Follicular Lymphoma | Stage III Follicular Lymphoma | Composite Lymphoma | Stage I Diffuse Large B-Cell Lymphoma | Stage I Follicular Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage II Follicular Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell Lymphoma and other conditions

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
Exelixis

Terminated

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Non-Hodgkin's Lymphoma (NHL) | Mantle Cell Lymphoma (MCL) | Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL)

United States
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Chinese PLA General Hospital

Recruiting

Decitabine and Anti-PD-1 in R/R DLBCL

Diffuse Large B Cell Lymphoma | Central Nervous System Lymphoma | Extranodal Extension | Relapse/Recurrence

China
Pell Bio-Med Technology Co., Ltd.

Recruiting

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
Massachusetts General Hospital
GlaxoSmithKline; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical...

Completed

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States
Synthekine

Recruiting

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | NHL | CLL/SLL | Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Januario Castro, M.D.
Memgen, LLC

Terminated

Study of Repeat Intranodal Injections of Ad-ISF35

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | Small Lymphocytic Lymphoma

United States
Ascenta Therapeutics

Completed

Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large Cell Lymphoma | Small Lymphocytic Lymphoma

United States
Weill Medical College of Cornell University
Epizyme, Inc.; Genentech, Inc.

Recruiting

Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Follicular Lymphoma | Diffuse Large B Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of California... and other collaborators

Active, not recruiting

Communication Skills Intervention to Promote Transition Into Survivorship

Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent... and other conditions

United States
Hoffmann-La Roche
Serbian Lymphoma Group

Completed

MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Serbia
Universität des Saarlandes
AstraZeneca; University of Leipzig; Wuerzburg University Hospital; University Hospital... and other collaborators

Recruiting

Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (ARCHED)

Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma

Germany
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Massachusetts General Hospital
Varian Medical Systems

Recruiting

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Lymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell Lymphoma

United States
Peter MacCallum Cancer Centre, Australia
Hoffmann-La Roche

Active, not recruiting

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (COALITION)

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma

Australia
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
National Cancer Institute (NCI)

Completed

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
Weill Medical College of Cornell University
Epizyme, Inc.; American Society of Clinical Oncology; Applebaum Foundation

Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Ann Arbor Stage II Diffuse Large B-Cell Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | AIDS-Related Lymphoma

United States
Adaptive Biotechnologies
Stanford University

Recruiting

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
Second Affiliated Hospital, School of Medicine,...
Ningbo Medical Center Lihuili Hospital; Huizhou Municipal Central Hospital; Taizhou... and other collaborators

Recruiting

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

Diffuse Large B-cell Lymphoma

China
University Medical Center Groningen
Takeda

Not yet recruiting

CD30 Imaging in Diffuse Large B-cell Lymphoma

Diffuse Large B-cell-lymphoma
Ruijin Hospital

Not yet recruiting

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Diffuse Large B Cell Lymphoma
Peking University People's Hospital
Peking University Cancer Hospital & Institute

Recruiting

Frontline of ASCT in High-risk DLBCL (Essential)

Diffuse Large B Cell Lymphoma

China
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research

Diffuse Large B-cell Lymphoma

China
Changhai Hospital
Nanjing Enricnk Biotech Co., Ltd

Recruiting

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Ningbo No. 1 Hospital
Zhejiang University

Recruiting

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

Diffuse Large B-cell Lymphoma

China
Jianfeng Zhou
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Weprom
Incyte Corporation; Resilience Care

Not yet recruiting

Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma (EMILY)

Diffuse Large B Cell Lymphoma

France
Zhejiang Cancer Hospital

Recruiting

ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL

Diffuse Large B Cell Lymphoma

China
Ruijin Hospital

Recruiting

Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Sweden, Hungary, Italy, Poland
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma

China
Swiss Group for Clinical Cancer Research

Recruiting

Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Diffuse Large B-cell Lymphoma

Switzerland, Italy

Clinical Trials on Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations